• electroCore announced published Long COVID trial results in Neuromodulation, showing symptom improvements with noninvasive autonomic neuromodulation compared with monitoring alone.
• The four-week randomized study enrolled 541 participants; 250 met final analysis criteria.
• Cervical vagus nerve stimulation, Sonocea’s acoustic technology and their combination improved symptoms; no active treatment demonstrated statistically significant superiority.
• Findings remain hypothesis-generating because the open-label study lacked a sham control and relied primarily on patient-reported outcomes.
• Neither technology has FDA clearance or approval for Long COVID; safety and effectiveness for the condition remain unestablished.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. electroCore Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120800PRIMZONEFULLFEED9876079) on November 12, 2026, and is solely responsible for the information contained therein.